

REMARKS

Applicant's attorney wishes to thank the Examiner for the careful consideration given to the present application. Applicant has added new claims 19-30 and has amended claims 7 and 8. Support for such an amendment may be found throughout the specification, including, for example, paragraphs [0131] and [0215]. Applicant addresses each of the rejections set forth in the Office Action in the order presented therein.

Related Applications

Initially, Applicant would like to draw the Examiner's attention to a related, co-pending application, specifically U.S. Application No. 10/366,751 (U.S. Publication No. 20030176512), which is currently pending and under appeal.

35 U.S.C. § 102(b)

The Examiner has rejected claims 7-18 under 35 U.S.C. § 102(b) as being anticipated by Oblong et al. as evidenced by Ashburn (U.S. Publication No. 20070010543). Applicant respectfully disagrees.


As amended, the claims are directed to a drug comprising a 2-imidazolyl disulfide and an acceptable carrier for intravenous administration, said 2-imidazolyl disulfide being useful in reducing or eliminating thioredoxin-associated apoptosis inhibition or inhibiting thioredoxin stimulated cell growth and new claims 19-30 are directed to a drug comprising a 2-imidazolyl disulfide and an acceptable carrier for oral administration, said 2-imidazolyl disulfide being useful in reducing or eliminating thioredoxin-associated apoptosis inhibition or inhibiting thioredoxin stimulated cell growth. The cited references fail to disclose a drug comprising a 2-imidazolyl disulfide and an acceptable carrier for intravenous or oral administration. At best, Oblong discloses a 2-imidazolyl disulfide in DMSO; however, DMSO is not an acceptable carrier for intravenous or oral administration. At best, DMSO may be a carrier for topical administration. Accordingly, Oblong, as evidenced by Ashburn, fails to anticipate the present claims, and this rejection should be withdrawn.

CONCLUSION

Applicant has timely filed this response. In the event that an additional fee is required for this response, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0436.

Should the Examiner have any questions or comments, or need any additional information from Applicant's attorney, he is invited to contact the undersigned at his convenience.

Respectfully submitted,

By: 
N. Nicole Endejann
Reg. No. 50,229

Dated: May 22, 2008
PEPPER HAMILTON LLP
500 Grant Street
One Mellon Bank Center, 50th Floor
Pittsburgh, PA 15219
(412) 454-5813
(412) 281-0717 - facsimile